- Fannie Mae to Tighten Lending Standards: Report
- Share Trading on London Stock Exchange Resumes
- China Overcapacity Worsening, EU Chamber Warns
- Investing in Good Karma – and Making a Profit
- Black Friday to Avoid Red Ink; Greenback Gets the Blues
- Wal-Mart Price Pressure Hurts China Workers: Report
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- Where Do Pardoned Turkeys Go?
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
MOST SHARED
- The Executive Job Search
- Chinese Overcapacity is Worsening, EU Chamber Warns
- Salvation Army's Kettles Now Credit Card-Ready
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Oil Friday
- China Unveils Carbon Target Ahead of Copenhagen
- Dubai Debt Delay Rattles Stock, Bond Markets
- Black Friday: Bargain or Bust?
- Wal-Mart Price Pressure Hurts China Workers: Report
Text Size 
 |
At least two five-star fund managers are looking past this week's market gyrations and offering investors what they think are some promising stock opportunities.
Michael Lippert of Baron Funds focuses on some Internet-related equities, while Michael Cuggino of Permanent Portfolio Funds sees biotech as a buy.
Lippert likes online diamond retailer Blue Nile [NILE
Loading...
()
].
"They're taking massive share from their competition," he told CNBC. "The online business model is just better than the offline model."
He also recommends Equinix [EQIX
Loading...
()
].
"They operate data centers that act as on-ramps of the Internet, so everything that's driving Internet growth is driving their business," he said.
Cuggino's biotech names include Amgen [AMGN
Loading...
()
].
"On Aranesp, we're hearing some news out of the FDA today," he said.
Aranesp and other anti-anemia drugs had combined sales of more than $6 billion last year.
"Genentech [DNA
Loading...
()
]'s another good name, especially recently, with their news on Avastin for breast cancer," he added.
The government's approval of Avastin to treat breast cancer earlier this year came as something of a surprise. Avastin had already been approved for the treatment of lung and colon cancer.
"Biotech's an area that's a little bit more defensive, but still hasn't participated in growth over the last several years, so it should, going forward," Cuggino said.
Print
Email
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
- How can you get out of debt and back on the road to recovery? Follow these ten steps.
Data is a real-time snapshot *Data is delayed at least 15 minutes